Cytokinetics Inc (CYTK) CEO exercises options and sells 7,500 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cytokinetics Inc President & CEO Robert I. Blum exercised non-qualified stock options for 7,490 shares of common stock at $10.60 per share and, on the same date, sold a total of 7,500 shares at $82.02 per share in open-market transactions, leaving 377,820 shares held directly and 2,083 shares held indirectly by each of two irrevocable trusts.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares ($615,150)
Net Sell
6 txns
Insider
Blum Robert I
Role
President & CEO
Sold
7,500 shs ($615K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 7,490 | $0.00 | -- |
| Sale | Common Stock | 10 | $82.02 | $820.20 |
| Exercise | Common Stock | 7,490 | $10.60 | $79K |
| Sale | Common Stock | 7,490 | $82.02 | $614K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 186,745 shares (Direct);
Common Stock — 377,820 shares (Direct);
Common Stock — 2,083 shares (Indirect, by Trust 1)
Footnotes (1)
- Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Key Figures
Shares Sold: 7,500 shares
Sale Price: $82.02 per share
Options Exercised: 7,490 shares
+5 more
8 metrics
Shares Sold
7,500 shares
Common stock sold in open-market transactions on 2026-07-13
Sale Price
$82.02 per share
Price for the 7,490-share and 10-share sales of common stock
Options Exercised
7,490 shares
Non-qualified stock options exercised into common stock on 2026-07-13
Exercise Price
$10.60 per share
Exercise price of the non-qualified stock options converted into common stock
Direct Holdings After
377,820 shares
Cytokinetics common stock held directly by Robert I. Blum after transactions
Trust Holdings After
2,083 shares each
Shares held by The Bridget Blum 2003 and The Brittany Blum 2003 Irrevocable Trusts
Remaining Options
186,745 options
Non-qualified stock options remaining under the exercised grant after 7,490-option exercise
Option Expiration
2027-02-28
Expiration date of the non-qualified stock option award exercised in part
Key Terms
Non-Qualified Stock Option (Right to Buy), open-market sale, indirect ownership, irrevocable trust
4 terms
Non-Qualified Stock Option (Right to Buy) financial
"Security title listed as "Non-Qualified Stock Option (Right to Buy)""
open-market sale financial
"Transaction action described as an "open-market sale" of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"Holdings reported as "I" for indirect ownership by family trusts"
irrevocable trust financial
"Shares held by The Bridget Blum 2003 and Brittany Blum 2003 Irrevocable Trusts"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
What insider transactions did CYTK CEO Robert I. Blum report on this Form 4?
Robert I. Blum reported exercising 7,490 stock options at $10.60 per share and selling 7,500 shares of Cytokinetics common stock at $82.02 per share, all dated July 13, 2026, as open-market sales and related option exercises.
What stock options did the CYTK CEO exercise in this filing?
Robert I. Blum exercised 7,490 non-qualified stock options for Cytokinetics common stock at an exercise price of $10.60 per share. These options relate to a grant exercisable from March 28, 2017 and expiring on February 28, 2027, reducing remaining option holdings.
What indirect CYTK holdings are reported through trusts for the CEO?
The filing shows 2,083 CYTK shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. These are reported as indirect ownership positions separate from Robert I. Blum’s directly held shares.
Did the CYTK CEO have remaining stock options after this exercise?
Yes. After exercising 7,490 options, 186,745 non-qualified stock options remain outstanding for Robert I. Blum under this specific option award. These options are exercisable into Cytokinetics common stock at an exercise price of $10.60 per share until February 28, 2027.